Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03878849 Org: User:
Start: 04/15/19 End: 09/30/27 Due: 09/30/28

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

Phase: N/A Priority: Normal
NCT ID: NCT03196947 Org: User:
Start: 06/13/17 End: 01/16/20 Due: 01/16/21

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase: N/A Priority: Normal
NCT ID: NCT04796324 Org: User:
Start: 03/01/21 End: 11/01/25 Due: 11/01/26

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Phase: N/A Priority: Normal
NCT ID: NCT01861496 Org: User:
Start: 04/30/13 End: 10/31/21 Due: 10/31/22

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05571969 Org: User:
Start: 02/20/23 End: 12/31/25 Due: 12/31/26

Clinical Pre-screening Protocol for Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03877796 Org: User:
Start: 04/11/19 End: 12/31/25 Due: 12/31/26

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase: N/A Priority: Normal
NCT ID: NCT03643107 Org: User:
Start: 10/17/18 End: 08/01/22 Due: 08/01/23

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Phase: N/A Priority: Normal
NCT ID: NCT03562832 Org: User:
Start: 06/20/18 End: 08/01/24 Due: 08/01/25